Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 5.1
edited by manuelmenendez
on 2025/01/27 23:04
Change comment: There is no comment for this version
To version 7.2
edited by manuelmenendez
on 2025/01/27 23:22
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,9 +2,10 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= Neurodiagnoses =
5 += //A new tridimensional diagnostic framework for CNS conditions// =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
7 +This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 +We aim to create a structured, interpretable, and scalable diagnostic tool.
8 8  )))
9 9  )))
10 10  
... ... @@ -12,8 +12,53 @@
12 12  (((
13 13  (% class="col-xs-12 col-sm-8" %)
14 14  (((
15 -= What can I find here? =
16 += What is this about and what can I find here? =
16 16  
18 +==== **Overview** ====
19 +
20 +The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
21 +
22 +* **Axis 1**: Etiology (genetic/sporadic and environmental factors).
23 +* **Axis 2**: Molecular Markers (biomarkers and proteinopathies).
24 +* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 +
26 +This methodology enables:
27 +
28 +* Greater precision in diagnosis.
29 +* Integration of incomplete datasets using AI-driven probabilistic modeling.
30 +* Stratification of patients for personalized treatment.
31 +
32 +==== **Diagnostic Axes** ====
33 +
34 +* (((
35 +**Axis 1: Etiology**
36 +
37 +* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
38 +* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
39 +* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
40 +)))
41 +* (((
42 +**Axis 2: Molecular Markers**
43 +
44 +* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
45 +* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
46 +* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
47 +)))
48 +* (((
49 +**Axis 3: Neuroanatomoclinical**
50 +
51 +* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
52 +* //Examples//: Hippocampal atrophy correlating with memory deficits.
53 +* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
54 +)))
55 +
56 +==== **Applications** ====
57 +
58 +This system enhances:
59 +
60 +* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
61 +* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
62 +
17 17  == Who has access? ==
18 18  
19 19  We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!